← Back to Analyst Consensus 
MAZE Buy
Maze Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 19
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 19, 2026 | Canaccord Genuity | initiate | — → Buy | — | 48% |
| Sep 24, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 23, 2026 | Citigroup | initiate | — → Buy | — | 54% |
| Sep 23, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Sep 22, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Aug 12, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Apr 14, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Mar 31, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Mar 25, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Mar 25, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 18, 2026 | Truist Securities | initiate | — → Buy | — | 54% |
| Mar 16, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Mar 10, 2026 | Mizuho | initiate | — → Outperform | — | 52% |
| Mar 9, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Mar 4, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jan 16, 2026 | BTIG | maintain | Buy → Buy | $46 | 52% |
| Dec 4, 2025 | Wells Fargo | initiate | — → Overweight | $55 | 54% |
| Dec 3, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $60 | 44% |
| Nov 7, 2025 | Wedbush | maintain | Outperform → Outperform | $36 | 58% |
| Sep 29, 2025 | JP Morgan | maintain | Overweight → Overweight | $37 | 55% |
| Sep 18, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $50 | 44% |
| Sep 15, 2025 | Guggenheim | maintain | Buy → Buy | $34 | 52% |
| Sep 12, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $50 | 44% |
| Sep 12, 2025 | BTIG | maintain | Buy → Buy | $37 | 52% |
| Sep 11, 2025 | BTIG | maintain | Buy → Buy | $37 | 52% |
| Sep 2, 2025 | BTIG | initiate | — → Buy | $30 | 52% |
| Jul 23, 2025 | HC Wainwright & Co. | initiate | — → Buy | $34 | 44% |
| Jul 8, 2025 | Wedbush | initiate | — → Outperform | $17 | 58% |
| Apr 2, 2025 | Guggenheim | reiterate | Buy → Buy | $19 | 52% |
| Feb 25, 2025 | Guggenheim | initiate | — → Buy | $19 | 52% |
| Feb 25, 2025 | Leerink Partners | initiate | — → Outperform | $28 | 51% |
| Feb 25, 2025 | JP Morgan | initiate | — → Overweight | $30 | 55% |
Price Target Trend
Jun 10, 2026 Latest: $62.54 Oct 24, 2026
EPS Estimates
+1q $-0.79
Lo: $-0.94 Hi: $-0.57
10 analysts ▲1
+1y $-3.19
Lo: $-4.28 Hi: $-2.31
10 analysts ▲1
0q $-0.75
Lo: $-0.87 Hi: $-0.56
10 analysts ▲1
0y $-2.73
Lo: $-3.06 Hi: $-2.07
10 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days